print

Pharmaceuticals

WHY AND HOW WE USE NEUTRONS?

CASE STUDIES

"Neutrons have proven themselves to be a key resource for this project; we needed to analyse the p7 protein structure in a specific environment. Now we can take this deep understanding of the virus not only to devices like biosensors, but also to other fields, to study the behaviour of membrane proteins in lipid bilayers, for example.” Bruno Tillier, Managing Director, Synthelis

NEWS CORNER

- Environment,Industry - Pharmaceuticals,Scientific news,D50-NeXT,Germany
- Health,Biology Health,Industry - Pharmaceuticals,Soft matter,Scientific news,IN13,IN16B,France,Italy
- News,Biology Health,Industry - Pharmaceuticals,Scientific news,DALI,LADI-III,USA
- Highlights 2021,News,Health,Biology Health,Industry - Pharmaceuticals,Scientific news
- Highlights 2021,Health,Biology Health,Industry - Pharmaceuticals,Scientific news
- News,Health,Biology Health,Industry - Pharmaceuticals,Soft matter,Press releases,Scientific news,D22,FIGARO,IN5,IN13,IN15,IN16B,Italy,Spain,United Kingdom
- News,Health,Biology Health,Industry - Pharmaceuticals,Scientific news,LADI-III,France
- Highlights,Highlights 2021,News,Health,Industry - Pharmaceuticals,Soft matter,Press releases,Scientific news,D17,FIGARO,France,Switzerland
- Highlights,Highlights 2021,Biology Health,Chemistry,Industry - Pharmaceuticals,Scientific news,LADI-III,Czech Republic,France
- LADI-III,USA,News,Biology Health,Industry - Pharmaceuticals,Press releases,Scientific news

Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders